Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Ventricular tachycardia (VT) in implantable cardioverter-defibrillator (ICD) patients increases morbidity and mortality, with shocks causing adverse effects.
• Antiarrhythmic drugs (AADs) have limited efficacy and side effects; catheter ablation carries risks but can be effective.
• Shared decision-making is crucial, considering patient status, comorbidities, and goals of care.

Purpose of the Study:

• To review the evidence for catheter ablation versus antiarrhythmic drug therapy in preventing ventricular tachycardia recurrence in ICD patients.
• To assess the effectiveness and comparative outcomes of ablation and AADs based on recent randomized trials.

Main Methods:

• Review of four published randomized trials for sustained monomorphic VT (SMVT) in ischemic heart disease.
• Analysis of the VANISH trial comparing catheter ablation to aggressive AAD therapy in ICD patients with prior infarction and SMVT.
• Subgroup analysis of patients with VT despite amiodarone therapy.

Main Results:

• The VANISH trial showed a 28% relative risk reduction in death, VT storm, and appropriate ICD shock with catheter ablation versus aggressive AADs (p=0.04).
• Catheter ablation demonstrated superior outcomes compared to escalating amiodarone or adding mexiletine in patients with VT despite amiodarone.
• Both catheter ablation and AADs (sotalol, amiodarone) are effective for VT in patients with myocardial infarction, ICDs, and VT.

Conclusions:

• Catheter ablation is a viable option for VT management in ICD patients, particularly when AADs fail or VT persists despite amiodarone.
• Early ablation may be considered in specific scenarios like slow VT, electrical storms, or hemodynamically unstable VT.
• Further research, including the VANISH-2 trial, is needed to determine optimal first-line therapy for VT post-ICD implantation.